Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 4Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Recurrence 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1

Interventions

pembrolizumab 439Carboplatin 323Nivolumab 291Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 254Paclitaxel 249Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 169atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Radiosurgery 114Oxaliplatin 114Pemetrexed 113Etoposide 111Fluorouracil 110venetoclax 108fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × 18-O-demethylcervinomycin A2 × Clear all
NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05445908 2026-05-08

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Active not recruiting
175 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡